Repligen Corporation research snapshot
RGEN AI stock analysis currently reads Repligen as a specialized bioprocessing supplier with real customer value, improving demand, and a demanding valuation. At the July 11, 2026 data cutoff, the latest public close was $144.24 and the verified market capitalization was about $8.14 billion. Repligen reported $194 million of first-quarter 2026 revenue, 11% organic growth, and $785 million of cash, cash equivalents, and marketable securities at March 31, 2026. The upside case depends on biologics production growth, chromatography and filtration adoption, margin recovery, and execution on its transformation plan. The main constraint is price: this RGEN AI stock analysis sees strong business quality but only medium investment certainty at roughly 158.5x trailing earnings and 76.7x trailing free cash flow. This page is for informational use and is not investment advice.
Current price
$144.24
Market cap
$8.14 billion
AI score
62 / 100
Rating
High-quality bioprocessing franchise with strong demand and valuation risk
Trend status
Above the 50-day and 200-day moving averages with positive but not extreme momentum
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Repligen sells filtration, chromatography, process analytics, proteins, and fluid-management technologies used to develop and manufacture biologic drugs. Customers pay when its tools improve yield, control, reliability, or production scale. | High |
| Moat | The moat comes from validated products, process know-how, installed workflows, switching friction, brand trust, and a portfolio built across upstream and downstream bioprocessing. It is meaningful, but large customers can negotiate and alternative suppliers remain active. | Medium |
| Management | Management has used acquisitions to broaden the portfolio and is now emphasizing site rationalization, product-line margin optimization, IT, and AI investment. The next test is whether transformation produces durable margin gains without weakening innovation or customer service. | Medium |
| Financial trend | FY2025 revenue rose 16.36% to $738.26 million and GAAP net income recovered to $48.89 million from a $25.51 million loss in 2024. TTM revenue was $763.34 million and TTM free cash flow was $106.04 million, although 2025 free cash flow was lower than 2024. | High |
| Valuation | At $144.24, the exact valuation check gives about 158.51x TTM EPS, 10.66x sales, 3.86x book value, and 76.72x free cash flow. The market is paying for a recovery in growth and profitability, so conventional margin of safety is limited. | High for the calculation |
| Technical trend | The July 10 snapshot put RGEN above its 50-day average of $125.54 and 200-day average of $139.52, with RSI at 61.95. The trend is constructive, but the stock is close enough to the longer average that a sustained break would weaken the setup. | Medium |
| Risk level | Risk is medium-high. Bioprocessing order cycles, customer inventory, large-account concentration, manufacturing execution, acquisitions, tariffs, foreign exchange, and valuation compression can all affect results. | High |
| AI confidence | AI confidence is high for disclosed facts and calculations, but medium for the forward thesis because no model can reliably know the timing of customer orders, industry recovery, or future multiples. | High for data, medium for outlook |
| Investment certainty | Investment certainty is medium-low: the business has credible technology and cash generation, while the current price requires sustained growth and better operating leverage to justify the valuation. | Medium-low |
RGEN AI stock forecast
The RGEN AI stock forecast is scenario-based rather than a promised price target. The required three-scenario calculation used $0.91 TTM EPS, three years, 22%, 14%, and 6% annual EPS growth, and 95x, 70x, and 45x exit PE assumptions. It produced calculated reference values of about $157, $94, and $49. The wider ranges below reflect uncertainty around bioprocessing demand, margins, acquisitions, and market multiples.
$150 to $180
More likely if 2026 guidance is met or exceeded, organic growth stays near the high end of 9% to 13%, chromatography and process analytics gain share, transformation lifts operating margins, and investors continue to value RGEN as a durable compounder.
$85 to $115
More likely if revenue grows but the recovery is uneven, 2026 adjusted EPS guidance of $1.97 to $2.05 is broadly achieved, and the valuation multiple normalizes toward a lower growth-company range. The calculated base reference was about $94.
$45 to $70
More likely if biopharma customers delay capacity spending, inventory correction returns, margins remain below plan, integration or transformation costs persist, or the market assigns a much lower multiple to slower cash-flow growth. The calculated bear reference was about $49.
RGEN AI technical analysis
RGEN AI technical analysis uses the latest public StockAnalysis snapshot available at the July 11, 2026 cutoff. RGEN closed at $144.24 on July 10, above the reported 50-day moving average of $125.54 and 200-day moving average of $139.52. RSI was 61.95, beta was 1.06, and average 20-day volume was 1.05 million shares. These are static reference levels, not live signals, so confirm them in a current chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $144.24 | Public close on July 10, 2026. Refresh the quote before using any technical framework. |
| Near support | $139.52 | Reported 200-day moving average at the cutoff. A sustained loss would weaken the longer trend. |
| Deeper support | $125.54 | Reported 50-day moving average at the cutoff. A decisive break would invalidate a medium-term trend-following setup. |
| Reference resistance | $150 to $160 | A round-number reference zone above the latest close, not a verified horizontal chart level. Use volume and price action to confirm any breakout. |
| 50-day moving average | $125.54 | Price was above this average in the July snapshot, supporting intermediate momentum. |
| 200-day moving average | $139.52 | Price was modestly above this average, so the longer trend has less room for error than the distance from the 50-day average suggests. |
| Momentum | RSI 61.95 | Positive momentum without an overbought reading in this snapshot. RSI can remain elevated during a trend and should not be used alone. |
| Volume | 20-day average 1.05 million shares | Above-average volume would make a breakout or breakdown more informative, especially around earnings and guidance. |
| Volatility | 5-year beta 1.06 | Historical beta was close to the market average, but bioprocessing order news can create event volatility beyond beta. |
| Invalidation | Decisive close below the live 200-day average, then $125.54 | A break below $139.52 would weaken the longer trend; a confirmed break below the live 50-day average would invalidate this trend framework. |
RGEN AI trading strategy
The RGEN AI trading strategy is a rules-based research framework, not personalized advice. It combines price confirmation with bioprocessing order trends, customer inventory, product mix, margin guidance, cash flow, acquisition execution, and the next earnings date.
Wait for RGEN to hold above the live 200-day average and for any move through the $150 to $160 reference zone to be confirmed by above-average volume and unchanged earnings assumptions. Review the upcoming earnings date and guidance before relying on a chart pattern.
Define risk before entry. A confirmed close below the live 200-day average near $139.52 can invalidate the longer trend framework, while a break below the 50-day average near $125.54 signals deeper weakness.
If RGEN pulls back toward $139.52 or $125.54 without a negative order or guidance update, wait for stabilization and compare volume with customer demand, gross margin, cash flow, and the valuation multiple before treating the move as mean reversion.
Do not average down solely because the stock fell. The setup fails if support breaks alongside weaker bioprocessing demand, delayed customer projects, margin pressure, or a reduced outlook.
Track organic revenue, adjusted operating margin, chromatography and process analytics growth, order trends, customer inventory, cash and marketable securities, free cash flow, acquisition integration, and the effect of the Polymem divestiture.
Refresh the forecast after earnings, guidance changes, a major acquisition, a customer concentration disclosure, a material tariff or foreign exchange move, or a large price gap. Avoid stale technical levels around results.
Investment research summary
Repligen supplies the tools and consumables that help biopharmaceutical companies develop, scale, and control production processes. Its customers pay for higher yield, shorter timelines, reproducibility, and lower process risk rather than for a single end drug.
The moat is built from validated products, process knowledge, regulatory and quality records, installed workflows, customer training, and a broad portfolio across filtration, chromatography, proteins, analytics, and fluid management. Switching costs are strongest when a product is embedded in a validated manufacturing process.
The thesis fails if customers reduce capacity spending, inventory remains elevated, alternatives take share, large accounts pressure price, acquisitions dilute returns, manufacturing quality slips, or new modality growth does not convert into recurring demand. A high multiple can amplify each disappointment.
Management expanded the platform through acquisitions and is now focused on a transformation office, site rationalization, product-line margin optimization, and faster IT and AI investment. The key capital-allocation question is whether operational savings and acquisitions produce better per-share cash returns than simply preserving financial flexibility.
Biologics, mRNA, cell and gene therapy, and continuous manufacturing increase the need for higher-productivity and better-controlled processes. The opportunity is real, but the timing depends on biotech funding, clinical success, customer plant utilization, and how much process value is captured by suppliers versus passed through to customers.
At $144.24, RGEN trades around 158.5x TTM earnings and 76.7x TTM free cash flow. The price assumes a meaningful improvement from the 2024 downturn and sustained growth beyond the 2026 guidance range. Margin of safety requires durable organic growth, operating leverage, and disciplined capital allocation, not just a large bioprocessing market.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Price, market capitalization, and shares | $144.24 July 10, 2026 close, $8.14 billion market cap, and 56.41 million shares. Price multiplied by shares matched reported market cap with a 0.04% variance. | StockAnalysis RGEN statistics | July 11, 2026 |
| FY2025 revenue and five-year trend | $738.26 million FY2025 revenue, up 16.36% year over year; 2024 revenue was $634.44 million and 2022 revenue was $801.54 million. | Repligen 2025 annual report and Macrotrends | July 11, 2026 |
| FY2025 profit and free cash flow | $48.89 million net income and $93.90 million free cash flow in FY2025. Macrotrends reports $91.93 million of FY2025 free cash flow, a 2.1% source difference that likely reflects presentation or cash-flow classification. | SEC filing, Macrotrends, and StockAnalysis | July 11, 2026 |
| Q1 2026 operating update and guidance | $194 million reported revenue, 11% organic growth, 55.7% GAAP gross margin, and FY2026 adjusted revenue guidance of $803 million to $833 million with adjusted diluted EPS guidance of $1.97 to $2.05. | Repligen Q1 2026 results | July 11, 2026 |
| Cash, debt, and net cash | $784.53 million cash and equivalents, $687.62 million debt, and $96.91 million net cash in the latest StockAnalysis snapshot. The company reported $785 million of cash, cash equivalents, and marketable securities at March 31, 2026. | StockAnalysis and Repligen Q1 2026 results | July 11, 2026 |
| Valuation ratios | 158.53 trailing PE, 10.66 price to sales, 3.86 price to book, 76.73 price to free cash flow, and 1.30% free cash flow yield. | StockAnalysis RGEN statistics | July 11, 2026 |
| Technical indicators | $144.24 price, $125.54 50-day average, $139.52 200-day average, RSI 61.95, beta 1.06, and 1.05 million 20-day average volume. | StockAnalysis RGEN statistics | July 11, 2026 |
| Addressable market and product scope | Repligen estimates a roughly $20 billion global bioprocessing product market and about $13 billion of addressable market at year-end 2025. Its product scope includes filtration, fluid management, chromatography, process analytics, and proteins. | Repligen 2025 annual report and company website | July 11, 2026 |
This RGEN AI stock analysis is an information tool, not investment advice, a solicitation, or a promise of returns. Forecast ranges are scenario estimates based on available data and assumptions, and they may be wrong. Verify current prices, filings, technical levels, taxes, liquidity, and your own risk tolerance before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
